Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.

American journal of respiratory and critical care medicine - 1 Dec 2021

Verma Renu, Patil Sunita, Zhang Nan, Moreira Flora M F, Vitorio Marize T, Santos Andrea da S, Wallace Ellen, Gnanashanmugam Devasena, Persing David H, Savic Rada M, Croda Julio, Andrews Jason R

Abstract excerpt

Rationale: Standardized dosing of antitubercular drugs contributes to a substantial incidence of toxicities, inadequate treatment response, and relapse, in part due to variable drug concentrations achieved. SNPs in the NAT2 (N-acetyltransferase-2) gene explain the majority of interindividual pharmacokinetic variability of isoniazid (INH). However, an obstacle to implementing pharmacogenomic-guided dosing is the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Arylamine N-Acetyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isoniazid

Share to Multiplex Polymerase Chain Reaction

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Share to Predictive Value of Tests

Share to Tuberculosis, Pulmonary

Source

Identifiers

PMID: 34375564
DOI: 10.1164/rccm.202103-0564OC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.PMID 34375564Read ↗

A rapid pharmacogenomic assay to detect <i>NAT2</i> polymorphisms and guide isoniazid dosing for tuberculosis treatmentSemantic proximity Read ↗

Pharmacogenomics and mutation informatics: correlation of NAT2 mutations and isoniazid acetylation rate.Semantic proximity Read ↗

Pharmacogenetic testing for NAT2 genotypes in a Tanzanian population across the lifespan to guide future personalized isoniazid dosing.Semantic proximity Read ↗

Genetic Landscape of NAT2 in the Moroccan Population: Implications for Isoniazid Pharmacogenetics in Tuberculosis.Semantic proximity Read ↗

A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.Semantic proximity Read ↗

Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.Semantic proximity Read ↗

Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.Semantic proximity Read ↗

A study of N-acetyltransferase 2 gene polymorphisms in the Indian population and its relationship with serum isoniazid concentrations in a cohort of tuberculosis patients.Semantic proximity Read ↗

Towards pharmacogenomics-guided tuberculosis (TB) therapy: N-acetyltransferase-2 genotypes among TB-infected Kenyans of mixed ethnicity.Semantic proximity Read ↗

A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosingSemantic proximity Read ↗

Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients.Semantic proximity Read ↗

Population pharmacokinetics of isoniazid in adult Indian tuberculosis patients: Evaluation of NAT2 polymorphisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.